Suppr超能文献

一种神经功能域方法,用于评估低工作记忆能力健康志愿者的认知和动机中的 D1/D5 多巴胺受体部分激动作用。

A Neurofunctional Domains Approach to Evaluate D1/D5 Dopamine Receptor Partial Agonism on Cognition and Motivation in Healthy Volunteers With Low Working Memory Capacity.

机构信息

Pfizer Worldwide Research and Development, Cambridge, MA.

California Clinical Trials Medical Group/PAREXEL International, Glendale, CA.

出版信息

Int J Neuropsychopharmacol. 2020 May 27;23(5):287-299. doi: 10.1093/ijnp/pyaa007.

Abstract

BACKGROUND

Dopamine D1 receptor signaling plays key roles in core domains of neural function, including cognition and reward processing; however, many questions remain about the functions of circuits modulated by dopamine D1 receptor, largely because clinically viable, selective agonists have yet to be tested in humans.

METHODS

Using a novel, exploratory neurofunctional domains study design, we assessed the safety, tolerability, pharmacodynamics, and pharmacokinetics of PF-06412562, a selective D1/D5R partial agonist, in healthy male volunteers who met prespecified criteria for low working memory capacity. Functional magnetic resonance imaging, electrophysiologic endpoints, and behavioral paradigms were used to assess working memory, executive function, and motivation/reward processing following multiple-dose administration of PF-06412562. A total of 77 patients were assigned PF-06412562 (3 mg twice daily and 15 mg twice daily) or placebo administered for 5 to 7 days. Due to the exploratory nature of the study, it was neither powered for any specific treatment effect nor corrected for multiple comparisons.

RESULTS

Nominally significant improvements from baseline in cognitive endpoints were observed in all 3 groups; however, improvements in PF-06412562-treated patients were less than in placebo-treated participants. Motivation/reward processing endpoints were variable. PF-06412562 was safe and well tolerated, with no serious adverse events, severe adverse events, or adverse events leading to dose reduction or temporary discontinuation except for 1 permanent discontinuation due to increased orthostatic heart rate.

CONCLUSIONS

PF-06412562, in the dose range and patient population explored in this study, did not improve cognitive function or motivation/reward processing more than placebo over the 5- to 7-day treatment period.

CLINICALTRIALS.GOV IDENTIFIER: NCT02306876.

摘要

背景

多巴胺 D1 受体信号在包括认知和奖励处理在内的核心神经功能领域中发挥着关键作用;然而,关于多巴胺 D1 受体调节的回路功能仍存在许多问题,这在很大程度上是因为目前还没有在人类中测试过临床可行的、选择性的激动剂。

方法

采用新型探索性神经功能领域研究设计,我们评估了选择性 D1/D5R 部分激动剂 PF-06412562 在符合低工作记忆能力预设标准的健康男性志愿者中的安全性、耐受性、药效学和药代动力学。功能性磁共振成像、电生理终点和行为范式用于评估在多次给药 PF-06412562 后工作记忆、执行功能和动机/奖励处理。共有 77 名患者被分配至 PF-06412562(每天两次 3mg 和每天两次 15mg)或安慰剂组,给药时间为 5-7 天。由于该研究的探索性质,它既没有针对任何特定的治疗效果进行计算,也没有进行多重比较校正。

结果

在所有 3 个治疗组中,与基线相比,认知终点均有显著的改善,但 PF-06412562 治疗组的改善幅度小于安慰剂组。动机/奖励处理终点则有所不同。PF-06412562 安全且耐受良好,无严重不良事件、严重不良事件或导致剂量减少或暂时停药的不良事件,除 1 例因直立性心动过速增加而永久停药外。

结论

在本研究中探索的剂量范围和患者人群中,PF-06412562 与安慰剂相比,在 5-7 天的治疗期间,并未改善认知功能或动机/奖励处理。

临床试验.gov 标识符:NCT02306876。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/826b/7251631/f47750c24553/pyaa007f0001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验